Advertisement
Screener

EXAGEN INC. (XGN) Overview

EXAGEN INC. (XGN) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.13; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.17; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.31; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.21; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.52$3.47$4.79$6.60$9.11$12.562025-09-292026-09-29$1.29$2.10$3.43$5.58$9.08$14.782021-09-292026-09-29$1.29$2.42$4.54$8.51$15.95$29.902019-09-192026-09-29$1.29$2.42$4.54$8.51$15.95$29.902019-09-192026-09-29$1.29$2.42$4.54$8.51$15.95$29.902019-09-192026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$8.30
Previous close
$8.48
Change
-$0.18
Change (%)
-2.12%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

XGN
+36.51%
S&P 500
(m)

1 year

XGN
-22.93%
S&P 500
(m)

3 years

XGN
+242.98%
S&P 500
(m)

5 years

XGN
-39.59%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.13

-0.39-0.28-0.17-0.060.0531 Mar 2025: estimate (m); actual -0.2031 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.2130 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.3130 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1731 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.1330 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.13(m)(m)
1 Jan 202631 Mar 2026(m)-0.17(m)(m)
1 Jul 202530 Sept 2025(m)-0.31(m)(m)
1 Apr 202530 Jun 2025(m)-0.21(m)(m)
1 Jan 202531 Mar 2025(m)-0.20(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.93

-2.85-2.30-1.75-1.20-0.6531 Dec 2021: estimate (m); actual -1.6831 Dec 2021(m)31 Dec 2022: estimate (m); actual -2.7731 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.3431 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.8331 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.9331 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.93(m)(m)
1 Jan 202431 Dec 2024(m)-0.83(m)(m)
1 Jan 202331 Dec 2023(m)-1.34(m)(m)
1 Jan 202231 Dec 2022(m)-2.77(m)(m)
1 Jan 202131 Dec 2021(m)-1.68(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 19.94M ■ Earnings -3.20M — Profit margin -16.03%

-10.33M-42.1%0.84M-33.1%12.01M-24.1%23.18M-15.0%30 Sept 2025: revenue 17.24M; earnings -7.09M; profit margin -41.10%30 Sept 202531 Dec 2025: revenue 16.63M*; earnings -4.67M*; profit margin -28.10%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 17.31M; earnings -3.97M; profit margin -22.92%31 Mar 202630 Jun 2026: revenue 19.94M; earnings -3.20M; profit margin -16.03%30 Jun 2026

31 Dec 2025 ■ Revenue 66.58M ■ Earnings -19.95M — Profit margin -29.97%

-61.06M-105.0%-13.96M-78.7%33.15M-52.4%80.25M-26.2%31 Dec 2022: revenue 45.56M; earnings -47.39M; profit margin -104.00%31 Dec 202231 Dec 2023: revenue 52.55M; earnings -23.69M; profit margin -45.08%31 Dec 202331 Dec 2024: revenue 55.64M; earnings -15.12M; profit margin -27.17%31 Dec 202431 Dec 2025: revenue 66.58M; earnings -19.95M; profit margin -29.97%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$8.30(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$8.30High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning XGN

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-18.92M
Profit margin
-26.61%
Return on assets · 12 month
-34.19%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
220.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
260.39K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-5.03%*
Total return · month
12.31%*
Total return · quarter
74.74%*
Total return · half year
209.70%*
Total return · year to date
36.51%*
Total return · 1 year
-22.93%*
Total return · 3 years
242.98%*
Total return · 5 years
-39.59%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$71.12M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
186.96%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

EXAGEN INC. Overview

View more →

(m)

(m)

SEC CIK
1274737
Industry (SIC)
8071 Services-Medical Laboratories
Country of operation
United States
Business address
1261 LIBERTY WAY, VISTA, California, 92081, United States
Fiscal year end
1231
Phone
(760) 560-1501

Similar stocks

Stock NameCountryMarket CapPE Ratio
Freenome, Inc. (FRNM)United States$0.143B
BIODESIX INC (BDSX)United States$0.312B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45